Research programme: antibacterials - Polyphor

Drug Profile

Research programme: antibacterials - Polyphor

Alternative Names: POL 7001; POL6137

Latest Information Update: 11 Jul 2017

Price : $50

At a glance

  • Originator Polyphor
  • Class Antibacterials; Macrocyclic compounds
  • Mechanism of Action Antimicrobial cationic peptide stimulants; Imp protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 22 Apr 2017 Antimicrobial data from a preclinical study in Gram-negative infections, including Pseudomonas infections, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID - 2017)
  • 09 Feb 2017 Preclinical development is ongoing in Switzerland (SC)
  • 20 Feb 2010 Preclinical development is ongoing Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top